Trial Profile

DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms DAPHNe

04 Jun 2024 Results assessing association of MRD with residual cancer burden and long-term outcomes presented at the 60th Annual Meeting of the American Society of Clinical Oncology
10 Dec 2022 Results(n=80) assessing Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab presented at the 45th Annual San Antonio Breast Cancer Symposium
21 Jan 2020 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com